Supplementary Table 3

Demographic evaluation of tobacco smoking history, clinical staging criteria, and α9-nAChR mRNA expression fold ratios of tumor vs normal

paired samples.

Patient Characteristic	Current Smokers (n= 18)	Passive Smokers (n=52)	Nonsmokers (n=104)
Clinical Breast Cancer Stage, No. (%)			
0	ND*	3 (5.8)	6 (5.8)
1	3 (16.7)	16 (30.8)	34 (32.7)
2	8 (44.4)	26 (50)	44 (42.3)
3	6 (33.3)	6 (11.5)	20 (19.2)
4	1 (5.6)	1 (1.9)	ND
Relative α9-nAChR mRNA expression in tumor vs normal tissue, No. (mean fold-difference, 95% CI)			
<1 fold difference (Normal > Tumor)	4 (0.83, 0.42 to 1.24) †	11 (0.37, 0.17 to 0.57)	43 (0.3, 0.01 to 0.6)
1–5 fold difference (Tumor > Normal)	8 (2.87, 1.33 to 4.42)	31 (2.59, 1.93 to 3.25)	61(2.37, 1.19 to 3.54)

>5 fold difference	6 (15.5, 8.95 to 22.05)	10 (6.22, 3.62 to 2.6)	ND
Total (Mean per group)	18 (6.62, 3.66 to 9.58) ‡	52 (2.81, 1.87 to 3.75)	104(1.51, 0.69 to 2.33)

* ND = not determined.

† *P* = .008 for current vs nonsmokers in comparisons using two-sided nonparametric Kruskal-Wallis and Mann-Whitney tests.

‡ *P* = .003. for current vs nonsmokers in comparisons using two-sided nonparametric Kruskal-Wallis and Mann-Whitney tests. A *P*-value ≤.05 was considered to be statistically significant.